Immunocompromised patients can still receive convalescent plasma
Adverse Events Mild, Rare With mAb Treatment for COVID-19 in Pregnancy
No differences seen in any obstetric-associated outcome or in composite 28-day COVID-19 outcome
Early Use of COVID-19 Convalescent Plasma Cuts Hospitalization Risk
Administration of convalescent plasma within nine days after symptom onset can reduce risk of COVID-19-linked hospitalization
Enhanced External Counterpulsation Eases ‘Long COVID’
Improvements seen in symptoms of fatigue, breathing difficulties, 6-minute walk test with EECP treatment
COVID-19 Convalescent Plasma Seems Safe for High-Risk Children
Recipient plasma neutralization titers were 6.2 percent of donor titers as early as 30 minutes after transfusion
COVID-19 Convalescent Plasma No Benefit for Most Patients
No association with clinical outcomes for typical patients; heterogeneity of treatment effect sizes seen across baseline characteristics
Casirivimab + Imdevimab Prevents Progression to Symptomatic COVID-19
For asymptomatic SARS-CoV-2-positive individuals living with infected household contact, combo cuts incidence of symptomatic COVID-19
Convalescent Plasma Not Efficacious in Hospitalized COVID-19 Patients
No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen
Convalescent Plasma Not Recommended in COVID-19
Guideline Development Group strongly recommends against its use in nonsevere COVID-19, recommends against use in severe, critical illness
Convalescent Plasma Unlikely to Improve Outcomes in Severe COVID-19
Likelihood of improvement in organ support-free days low in critically ill adults with COVID-19 receiving convalescent plasma